Lysergic acid diethylamide

Paul Stamets advocates for treating psilocybin mushrooms as nonaddictive, life-changing substances, not 'shrooms' or party drugs. Clinical trials show psilocybin can significantly improve treatment-resistant depression and other conditions. The FDA has designated psilocybin a breakthrough medicine. Psychedelics like psilocybin and LSD affect brain connectivity and neuroplasticity, offering potential benefits for various mental health issues. Microdosing, taking tiny amounts of psilocybin, is suggested for maintaining brain health, though scientific benefits are unproven. Side effects and risks exist, including potential psychosis triggers. Researchers aim to develop non-psychedelic drugs that mimic psychedelics' benefits.

U.S. roadside drug testing market size was USD 1.45 billion in 2023, expected to reach USD 2.28 billion by 2033, growing at a CAGR of 4.65%. Alcohol segment dominated with 31.96% share in 2023, while cannabis/marijuana segment is projected to grow at the highest CAGR of 5.50%. Breath segment led with 44.44% share in 2023, and highway police segment dominated with 90.87% share. Market growth attributed to rising drug use, legalization of marijuana, and increasing awareness of drug-impaired driving. California led with 14.58% revenue share in 2023, driven by large population and progressive drug regulations.

MindBio Therapeutics reports MB22001, a microdosing formulation of LSD, has achieved 12-month shelf stability at room temperature, crucial for regulatory compliance and patient ease of use. MB22001, currently in Phase 2B trials, has shown significant antidepressant effects and a favorable safety profile, with sustained responses up to 3 months post-treatment.

A study at Tata Institute of Fundamental Research used psychedelic drug DOI to identify a neuron activating the ventral hippocampus, potentially reducing anxiety without hallucinations, paving the way for targeted treatments for anxiety disorders and treatment-resistant conditions like PTSD and depression.

Companies like Mindstate Design Labs and Beckley Psytech are developing 'next generation' psychedelics to reduce risks and improve efficacy, aiming to make treatments more palatable to regulators and patients.

A study from Spain’s Universidad de las Palmas de Gran Canaria found that a low dose of LSD is a safe and effective treatment for dog anxiety, with no adverse side effects.

The DEA proposed increasing psilocybin, psilocin, and ibogaine production quotas by 50% for 2025, signaling support for psychedelic research. This follows a growing interest in studying these compounds for mental health treatments, despite their Schedule 1 status. The VA is also increasingly involved in psychedelic-assisted therapy research for veterans.

Water Tower Research published a report on Cybin, Inc., highlighting its leadership in neuropsychiatric therapeutics, rapid advancement of lead candidates CYB003 and CYB004, and differentiated deuteration technology. Cybin's market valuation is favorable compared to peers, and its well-capitalized status positions it for potential success.

Water Tower Research published an Initiation of Coverage Report on Cybin, Inc., highlighting its status as a leader in novel neuropsychiatric therapeutics. Cybin's focus on innovative treatments for mental health disorders like MDD and GAD, with lead candidates CYB003 and CYB004, positions it favorably compared to peers. The report emphasizes Cybin's rapid pipeline advancement and differentiated solutions, noting its favorable valuation and well-capitalized status.